Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NYESO-1c259 T cells · 1 trial · 1 indication
Number of Participants with Adverse Events related to study treatment
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | This is an open label clinical trial. Patients with the HLA-A201, HLA-A205, and/or HLA-A206 allele and whose tumor expresses the NY-ESO-1 tumor antigen will be eligible to receive NYESO-1c259 T cells. |
| Name | Type | Description |
|---|---|---|
| NYESO-1c259 T cells | BIOLOGICAL | Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion. |
Inclusion Criteria: * Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ≥ 2 lines of chemotherapy * Age ≥ 18 years of age * No significant immunodeficiency * Have been informed of ...
Top 20 of 60 competitors
NYESO-1c259 T cells are an investigational cell therapy being studied for ovarian cancer. They are engineered T cells designed to recognize the NY-ESO-1 cancer antigen. The therapy is being developed by Adaptimmune Therapeutics PLC, which trades on the Nasdaq under the ticker ADAP.
NYESO-1c259 T cells are being studied as a treatment for ovarian cancer. The single clinical trial of this therapy enrolled nine patients with ovarian cancer in the United States. It is an investigational therapy and is not approved for commercial use in ovarian cancer or any other indication.
NYESO-1c259 T cells are being developed by Adaptimmune Therapeutics PLC, which is listed on the Nasdaq under the ticker ADAP. The company is the sponsor of the clinical program evaluating this engineered T cell therapy in ovarian cancer.
NYESO-1c259 T cells are in Phase 1 clinical development. The program consists of one completed Phase 1 trial, and there are currently no active trials of this therapy. It remains investigational and has not been approved by the FDA.
NYESO-1c259 T cells have been evaluated in one clinical trial, NCT01567891, titled CT Antigen TCR-redirected T Cells for Ovarian Cancer. The Phase 1 trial enrolled nine patients with ovarian cancer in the United States and is now completed. No other trials of this therapy are listed.